Lithera, Inc. Appoints Thomas Wiggans to Board of Directors
April 04, 2011 09:00 ET
|
Neothetics
SAN DIEGO, April 4, 2011 (GLOBE NEWSWIRE) -- Lithera, Inc. announced today the appointment of Thomas G. Wiggans to its Board of Directors.
"Lithera is making substantial progress with LIPO-102 by...
Lithera Announces the Appointment of George W. Mahaffey as President and Chief Executive Officer
March 21, 2011 09:00 ET
|
Neothetics
SAN DIEGO, March 21, 2011 (GLOBE NEWSWIRE) -- Lithera, Inc. today announced the appointment of George W. Mahaffey as President and Chief Executive Officer. Mr. Mahaffey will also join the Lithera...
Lithera Reports Positive Clinical Study Results From a Phase IIb Trial for LIPO-102, a Novel Treatment for Localized Fat Reduction
November 03, 2010 09:00 ET
|
Neothetics
SAN DIEGO, Nov. 3, 2010 (GLOBE NEWSWIRE) -- Lithera, Inc. today announced positive results from a Phase IIb clinical study of LIPO-102, its novel injectable combination of salmeterol xinafoate (SX)...
Lithera Announces Notice of Allowance for a Key Patent Application for LIPO-102, a Novel Treatment for Localized Fat Reduction
October 12, 2010 09:00 ET
|
Neothetics
SAN DIEGO, Oct. 12, 2010 (GLOBE NEWSWIRE) -- Lithera, Inc. today announced receipt of a Notice of Allowance from the U.S. Patent and Trademark Office for a patent application broadly covering...
Lithera Reports Positive Clinical Study Results From a Second Phase IIa Trial for LIPO-102, a Novel Treatment for Localized Fat Reduction
May 05, 2010 09:00 ET
|
Neothetics
SAN DIEGO, May 5, 2010 (GLOBE NEWSWIRE) -- Lithera, Inc. today announced positive results from a Phase IIa clinical study of LIPO-102, its novel injectable combination of salmeterol xinafoate (SX) and...
Lithera Reports Positive Phase IIa Clinical Study Results for LIPO-102, a Novel Treatment for Localized Fat Reduction
March 09, 2010 09:00 ET
|
Neothetics
SAN DIEGO, March 9, 2010 (GLOBE NEWSWIRE) -- Lithera, Inc. today announced positive results from a Phase IIa clinical study of LIPO-102, its novel injectable combination of salmeterol xinafoate (SX)...
Lithera Obtains Orphan Drug Product Designation for LIPO-102
February 23, 2010 09:00 ET
|
Neothetics
SAN DIEGO, Calif., Feb. 23, 2010 (GLOBE NEWSWIRE) -- Lithera, Inc. today announced the receipt of Orphan Drug Product Designation for LIPO-102 for the treatment of symptomatic exophthalmos associated...
Lithera Successfully Completes Phase I Clinical Trial of LIPO-102
February 09, 2010 09:00 ET
|
Neothetics
SAN DIEGO, Feb. 9, 2010 (GLOBE NEWSWIRE) -- Lithera, Inc. today announced the successful completion of a three-part Phase I clinical trial of LIPO-102 being developed for the treatment of...